An Open-label Study of XEN1101 in Epilepsy
X-TOLE4
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy
2 other identifiers
interventional
880
22 countries
137
Brief Summary
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2023
Longer than P75 for phase_3
137 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 13, 2023
CompletedFirst Posted
Study publicly available on registry
February 8, 2023
CompletedStudy Start
First participant enrolled
April 25, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2033
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2033
April 13, 2026
April 1, 2026
9.9 years
January 13, 2023
April 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The adverse events
To assess the safety and tolerability of XEN1101
From the start of treatment in the open-label extension (OLE) study through 8 weeks after the last dose.
Secondary Outcomes (5)
Change in monthly seizure rate
From baseline through the active extension treatment (Week 312).
Proportion of responders
From baseline through the active extension treatment (Week 312).
Change in Clinical Global Impression of Severity (CGI-S)
From baseline through the active extension treatment (Week 312).
Change in Patient Global Impression of Severity (PGI-S)
From baseline through the active extension treatment (Week 312).
Change in Quality of Life in Epilepsy Inventory (QOLIE-31)
From baseline through the active extension treatment (Week 312).
Study Arms (1)
XEN1101 15 or 25 mg/day
EXPERIMENTALXEN1101 15 or 25 mg/day
Interventions
Eligibility Criteria
You may qualify if:
- Subject must be properly informed of the nature and risks of the study and give informed consent in writing prior to entering the study (for adult subjects) and for adolescent subject's parent/legal guardian and subject gives informed consent or assent in writing prior to entering the study.
- Subject must have successfully completed the double-blind treatment period (DBP) and have not terminated early from Study X-TOLE2, X-TOLE3, or X-ACKT, met all eligibility requirements, and had no important protocol deviations (in the opinion of the sponsor) or adverse events (AEs) (in the opinion of the investigator) that would preclude the subject's entry into the long-term extension study.
- In the opinion of the investigator, the subject is able to understand verbal and written instructions and will adhere to all study schedules and requirements.
- Subject is able to keep accurate seizure diaries.
You may not qualify if:
- Subject met any of the withdrawal criteria while in Study X-TOLE2, X-TOLE3, or X-ACKT.
- Subject has any medical condition, personal circumstance, or ongoing AE (from Study X-TOLE2, X-TOLE3, or X-ACKT) that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study, or prevents adherence to the protocol.
- Subject is planning to enter a clinical study with a different investigational drug or planning to use any experimental device for treatment of epilepsy or any other medical condition during the study and until 28 days after completion of this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xenon Pharmaceuticals Inc.lead
- Worldwide Clinical Trialscollaborator
Study Sites (146)
Xenoscience
Phoenix, Arizona, 85004, United States
University of Arizona - Health Sciences
Tucson, Arizona, 85724, United States
Clinical Trials, Inc
Little Rock, Arkansas, 72205, United States
Brain Science Research Institute
Los Angeles, California, 90025, United States
UC Irvine Health
Orange, California, 92868, United States
University of California, Davis Clinical & Translational Science Center Clinical Research (CCRC)
Sacramento, California, 95817, United States
University of Colorado Hospital Anschutz Outpatient Pavilion
Aurora, Colorado, 80045, United States
Mayo Clinic Florida
Jacksonville, Florida, 32224, United States
Serenity Research Center, LLC
Miami, Florida, 33176, United States
Research Institute of Orlando, LLC
Orlando, Florida, 32806, United States
Panhandle Research & Medical Clinic
Pensacola, Florida, 10021, United States
University of South Florida
Tampa, Florida, 33606, United States
Encore Medical Research of Weston, LLC
Weston, Florida, 33331, United States
Hawaii Pacific Neuroscience
Honolulu, Hawaii, 96817, United States
Consultants in Epilepsy and Neurology
Boise, Idaho, 83704, United States
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
The University of Kansas Medical Center
Kansas City, Kansas, 66103, United States
Bluegrass Epilepsy Research, LLC
Lexington, Kentucky, 40504, United States
Kentucky Clinic
Lexington, Kentucky, 40536, United States
MMP Neurology
Scarborough, Maine, 04074, United States
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland, 20817, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
UMass Chan Medical School
Worcester, Massachusetts, 06155, United States
University of Michigan Hospitals
Ann Arbor, Michigan, 48109-2435, United States
Wayne State University
Detroit, Michigan, 48201, United States
Michigan State University
East Lansing, Michigan, 48824, United States
Cornwell Health (Spectrum Health Hospitals)
Grand Rapids, Michigan, 49503, United States
Minneapolis Clinic of Neurology
Burnsville, Minnesota, 55337, United States
Saint Louis University Medical School
St Louis, Missouri, 63104, United States
Northeast Epilepsy Group
Hackensack, New Jersey, 07601, United States
Dent Neurosciences Research Center
Buffalo, New York, 14226, United States
New York University Comprehensive Epilepsy Center
New York, New York, 10016, United States
Mount Sinai Health
New York, New York, 10029, United States
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
Montefiiore Medical Center
The Bronx, New York, 10467, United States
Onsite Clinical Solutions
Charlotte, North Carolina, 28211, United States
Duke University
Durham, North Carolina, 27710, United States
Meridian Clinical Research, LLC
Raleigh, North Carolina, 27607, United States
Summa Health
Akron, Ohio, 44304, United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
The Ohio State University Brain and Spine Hospital
Columbus, Ohio, 43210, United States
Providence Neurological Specialities
Portland, Oregon, 97225, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Austin Epilepsy Care Center
Austin, Texas, 78758, United States
ANESC Research
El Paso, Texas, 79912, United States
UT Health San Antonio
San Antonio, Texas, 78229, United States
University of Utah Clinical Neurosciences Center
Salt Lake City, Utah, 84132, United States
Carilion Clinic
Roanoke, Virginia, 24013, United States
Sentara Neurology Specialists
Virginia Beach, Virginia, 23456, United States
University of Washington Main Hospital
Seattle, Washington, 10012, United States
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, 53215, United States
Hospital General de Agudos "José M. Ramos Mejía"
Buenos Aires, 1221, Argentina
Asociacion Medica de Lomas de Zamora S.A. - Policlinicio Lomas
Buenos Aires, B1832BQD, Argentina
STAT Research S.A.
Buenos Aires, C1023AAB, Argentina
Centro de Psicología Médica San Martín de Tours SRL (CITES-INECO)
Buenos Aires, C1060AAF, Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, C1199ABB, Argentina
CENyR, Centro de Especialidades Neurologicas u Rehabilitacion
Buenos Aires, C1424BYD, Argentina
FLENI (Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia)
Buenos Aires, C1428DGG, Argentina
Hospital Córdoba
Córdoba, X5000, Argentina
Hospital De Alta Complejidad en Red El Cruce - Dr Nester Carlos Kirchner Servicio de Atencion Medica Integral Para la Communidad
San Juan Bautista, 1888, Argentina
Sanatorio del SUR S.A.
San Miguel de Tucumán, 4000, Argentina
Prince of Wales Hospital
Randwick, New South Wales, 2031, Australia
Royal Prince Alfred Hospital
Camperdown, 2050, Australia
St Vincent's Hospital Melbourne
Fitzroy, 3065, Australia
Austin Health Pharmacy Clinical Trials
Heidelberg, 3084, Australia
Southern Neurology
Kogarah, 2217, Australia
Alfred Hospital Neurology CT Dept of Neuroscience
Melbourne, 30004, Australia
The Royal Melbourne Hospital
Parkville, 3050, Australia
Mater Misericordiae Ltd South Brisbane
South Brisbane, 4101, Australia
Westmead Hospital Dept. of Neurology Epilepsy Unit
Westmead, 2145, Australia
University Hospital Innsbruck
Innsbruck, 6020, Austria
Universitatsklinik fur Neurologie, Medizinische Universitat Wien
Vienna, 1090, Austria
Cliniques Universitaires Saint-Luc (UCL)
Brussels, 1200, Belgium
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
Hospital for active treatmnt Puls AD Neurology Dpt
Blagoevgrad, 2700, Bulgaria
MHATNP St. Naum
Sofia, 1113, Bulgaria
Center for Neurologic Research
Lethbridge, Alberta, T1J 0N9, Canada
London Health Sciences Center
London, Ontario, N6A 5A5, Canada
Le Centre Hospitalier de l'Universite' de Montreal (CHUM)
Montreal, H2X 0C1, Canada
Centro de investigación Clinica UC
Santiago, 8330073, Chile
Hospital Clinico Viña del Mar
Viña del Mar, 2520612, Chile
Altavita Centar j.d.o.o.
Zagreb, 10000, Croatia
Poliklinika Bonifarm
Zagreb, 10000, Croatia
University Hospital Centre Zagreb
Zagreb, 10000, Croatia
Motol University Hospital
Prague, 150 06, Czechia
Forbeli s.r.o.
Prague, 160 00, Czechia
Hopital Neurologique Pierre Wertheimer, Hospices Civils de Lyon
Lyon, 69003, France
Hôpital Fondation Adolphe de Rothschild
Paris, 75010, France
Hôpitaux Universitaires Pitié Salpêtrière
Paris, 75013, France
CHU De Rennes - Hôpital Pontchaillou
Rennes, 35033, France
Hôpital de Hautepierre
Strasbourg, 67200, France
American Hospital Network LLC
Tbilisi, 0102, Georgia
Institute of Neurology and Neuropsychology
Tbilisi, 0186, Georgia
Universitätsklinikum Aachen
Aachen, 52074, Germany
Krankenhaus Mara gGmbH
Bielefeld, 33617, Germany
Universitätsklinikum, ZNN - Epilepsiezentrum Frankfurt Rhein-Main
Frankfurt, 60528, Germany
University Hospital Freiburg
Freiburg im Breisgau, 79106, Germany
Philipps-Universität Marburg
Marburg, 35043, Germany
Klinikum der Universität München
München, 81377, Germany
Universitaets-Und Rehabilitations Ulm (RKU)
Ulm, 89081, Germany
Semmelweis Egyetem, Idegsebeszeti es Neurointervencios Klinika
Budapest, 1145, Hungary
Beaumont Hospital
Dublin, NO9 V2NO, Ireland
Hadassah Medical Center (HMC)
Jerusalem, 9112001, Israel
Kaplan Medical Center (KMC)
Rehovot, 76100, Israel
The Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
IRCCS Istituto delle Scienze Neurologiche Bologna
Bologna, 40139, Italy
Universita' Degli Studi Gabriele d'Annunzio Di Chieti
Chieti, 66100, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126, Italy
Azienda Ospedaliero Universitaria Policlinico Umberto I
Roma, 00185, Italy
Human Science Research Trials
Mexico City, 14050, Mexico
Grupo Medico Camino SC
Mexico City, 3310, Mexico
Neurociencias Estudios Clínicos SC
Sinaloa, Mexico
University of Auckland
Auckland, 1023, New Zealand
Waikato Hospital
Hamilton, 3204, New Zealand
Centrum Medyczne Neuromed
Bydgoszcz, 85-163, Poland
COPERNICUS Podmiot Leczniczy Sp. z o.o.
Gdansk, 80-803, Poland
NZOZ Neuromed M. i M.
Lublin, 20-064, Poland
Twoja Przychodnia Nowosolskie Centrum Medyczne
Nowa Sól, 67-100, Poland
MTZ Clinical Research Powered by Pratia
Warsaw, 02-172, Poland
Neurosphera Sp z o.o.
Warsaw, 03-829, Poland
Centro Hospitalar Universitário de Coimbra (CHUC)
Coimbra, 3000-075, Portugal
Hospital Senhora da Oliviera de Guimaraes
Guimarães, 4835-044, Portugal
Centro Hospitalar Lisboa Ocidental, EPE - Hospital Egas Moniz
Lisbon, 1349-019, Portugal
Centro Hospitalar Universitario de Santo António, E.P.E
Porto, 4050-342, Portugal
Unidade Local de Saúde de São João
Porto, 4200-319, Portugal
Unidade Local Saúde Matosinhos
Porto, 4464-513, Portugal
Centro Hospitalar de Entre o Douro e Vouga
Santa Maria da Feira, 520-211, Portugal
Hospital Universitario Cruces
Barakaldo, 48903, Spain
Vall d'Hebron Hospital
Barcelona, 08035, Spain
Hospital Vithas La Milagrosa
Madrid, 28010, Spain
Hospital Ramón Y Cajal
Madrid, 28034, Spain
Hospital Ruber Internacional
Madrid, 28034, Spain
Hospital Clinico San Carlos
Madrid, 28040, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
Hospital Regional De Malaga
Málaga, 29010, Spain
Hospital La Fe
Valencia, 46026, Spain
Hospital Clinico Universitario de Valladolid
Valladolid, 47003, Spain
Leeds Teaching Hospitals NHS Trust
Leeds, England, LS97TF, United Kingdom
Cardiff and Vale UHB
Cardiff, Wales, CF14 4XW, United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham, B15 2TH, United Kingdom
St George's Hospital NHS Foundation Trust
London, SW17 0RE, United Kingdom
University College London
London, WC1N 3BG, United Kingdom
John Radcliffe Hospital
Oxford, OX39DU, United Kingdom
Salford Royal NHS Foundation Trust - Greater Manchester Neuroscience Centre (GMNC)
Salford, M6 8HD, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Director
Xenon Pharmaceuticals Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 13, 2023
First Posted
February 8, 2023
Study Start
April 25, 2023
Primary Completion (Estimated)
April 1, 2033
Study Completion (Estimated)
June 1, 2033
Last Updated
April 13, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share